Republic of the Congo (Concluded)

Republic of the Congo (Concluded)

Study Site: Bouenza


Analysis of MDA for LF in L. Loa Endemic Countries

Optimization of Mass Drug Administration with Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Congo Brazzaville
Study Site: Bouenza

The purpose of this community study is to determine the impact of MDA with Albendazole (400 mg, twice per year) on LF and STH in Central Africa. Interim results from this project are very encouraging regarding the potential of albendazole alone to control LF and STH. Preliminary results from the community trial are reported in a paper that has been accepted for publication in the American Journal of Tropical Medicine and Hygiene. The final re-examination was completed in 2015. Final lab results are currently being analyzed.

Implementation Partners

Research Collaborator

Ministry of Health and Population
Brazzaville, Congo
Dr. Francois Missamou, Director of Epidemiology & Disease Control

Coordinating Institution

Institut de Recherche pour le Developpment Montpellier, France
Dr. Michel Boussinesq, Directeur de Recherche